Financial Performance - The company's operating revenue for Q3 2025 was ¥156,896,637.59, a decrease of 3.89% compared to the same period last year[4] - The total profit for the period was ¥59,860,449.63, down 29.69% year-on-year[4] - The net profit attributable to shareholders was ¥50,989,335.80, reflecting a decline of 30.15% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥38,088,546.93, a significant drop of 46.80% year-on-year[4] - Total operating revenue for the first three quarters of 2025 reached ¥459,324,004.23, an increase of 7.9% compared to ¥427,255,735.56 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥177,008,199.81, a decrease of 10.3% from ¥197,452,784.89 in the previous year[20] - The company reported a total profit of ¥208,990,845.31 for the first three quarters of 2025, compared to ¥230,234,444.81 in the previous year, reflecting a decline of 9.2%[20] Research and Development - Research and development (R&D) expenses totaled ¥22,697,881.25 for the quarter, an increase of 45.65% compared to the same period last year[5] - R&D expenses accounted for 14.47% of operating revenue, up 4.92 percentage points from the previous year[5] - Research and development expenses rose to ¥57,155,686.84, reflecting a 37.6% increase compared to ¥41,435,654.28 in the same period last year[19] Assets and Liabilities - The total assets at the end of the period were ¥2,596,450,644.01, an increase of 1.83% from the end of the previous year[5] - Total current assets are reported at ¥1,880,374,485.51, down from ¥1,894,390,045.41 in the previous year[15] - Total non-current assets increased to ¥716,076,158.50 from ¥655,388,198.52, reflecting a growth of about 9.25%[16] - Total liabilities decreased to ¥108,345,513.01 from ¥152,666,866.13, indicating a reduction of 29%[19] - Total equity increased to ¥2,488,105,131.00, up from ¥2,397,111,377.80, representing a growth of 3.8%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥119,637,771.27, down 44.76% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥119,637,771.27, down 44.8% from ¥216,593,741.59 in the first three quarters of 2024[23] - Net cash flow from investment activities was -$37.93 million, a decrease from -$1.25 billion year-over-year[24] - Cash inflow from financing activities totaled $21.39 million, while cash outflow was $111.34 million, resulting in a net cash flow of -$89.95 million[24] - The ending balance of cash and cash equivalents was $1.02 billion, down from $1.95 billion at the beginning of the period[24] - Cash outflow from investment activities totaled $7.93 billion, compared to $3.64 billion in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,567[12] - The largest shareholder, Hangzhou Yijia Investment Management Co., Ltd., holds 26,450,057 shares, accounting for 32.66% of total shares[12] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[14] - There are no significant changes in the shareholder structure or related party transactions reported[13] - Other comprehensive income after tax amounted to ¥424,287.74, significantly higher than ¥142,379.15 in the same period last year[20] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25]

Summary of Key Points Core Viewpoint - The company announced the completion of a share reduction plan by its shareholder, Suzhou Yuan Sheng Private Fund Management Partnership, which involved a total reduction of 345,816 shares, representing 0.4270% of the total share capital [1][2]. Group 1: Shareholder Holdings - Before the reduction plan, the shareholder "Xin Jian Yuan" held 3,233,835 shares, accounting for 3.9934% of the company's total share capital, with shares acquired from the company's initial public offering and through the distribution of bonus shares in 2023 [1]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on July 3, 2025, with a maximum intended reduction of 1,622,700 shares (2.0039% of total shares), including up to 809,700 shares through centralized bidding and 813,000 shares through block trading, scheduled from July 25, 2025, to October 23, 2025 [1]. - As of October 23, 2025, the shareholder successfully reduced 345,816 shares through centralized bidding, with no shares sold via block trading, concluding the reduction plan [2][3].

Summary - The core point of the article is that Anjisi (688581.SH) has completed a share reduction plan, with a total of 345,800 shares reduced by the shareholder Xinjianyuan, representing 0.4270% of the total share capital [1] Group 1 - Anjisi received a notice from shareholder Xinjianyuan regarding the share reduction results [1] - As of October 23, 2025, Xinjianyuan reduced 345,800 shares through centralized bidding, accounting for 0.4270% of the total share capital [1] - No shares were reduced through block trading, which accounted for 0.000% of the total share capital [1]

Group 1 - The core point of the news is that Anjisi (SH 688581) announced the completion of a share reduction plan by its shareholder, Xinjianyuan, who reduced approximately 350,000 shares, accounting for 0.427% of the total share capital [1] - As of October 23, 2025, Xinjianyuan reduced shares through centralized bidding, totaling about 350,000 shares, with no shares reduced through block trading [1] - For the year 2024, Anjisi's revenue composition is heavily weighted towards medical devices, which account for 99.41% of total revenue, while other businesses contribute only 0.59% [1] Group 2 - As of the latest report, Anjisi's market capitalization stands at 5.3 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals, totaling $80 billion this year, indicating a robust secondary market for biomedicine [2] - Despite the hot secondary market, the primary market for fundraising in the biomedicine sector is experiencing a cooling trend, as noted by a partner at a venture capital firm [2]

证券代码：688581 证券简称：安杰思 公告编号：2025-063 杭州安杰思医学科技股份有限公司 本次减持计划实施前，公司苏州元生私募基金管理合伙企业（有限合伙）－ 苏州工业园区新建元二期创业投资企业（有限合伙）（以下简称"新建元"）持有 3,233,835 股，占公司总股本的 3.9934%，其中持有的股份来源为公司首发前股份 数 2,309,882 股，通过公司 2023 年年度派送红股获得的股份数 923,953 股。上述 股东持有的公司首发前股份已于 2024 年 5 月 20 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 7 月 3 日，公司于上海证券交易所网站（www.sse.com.cn）披露了《杭 州安杰思医学科技股份有限公司股东减持股份计划公告》（公告编号：2025-045）。 因企业自身的经营安排，股东新建元拟合计减持公司股份不超过 1,622,700 股（即 不超过公司股份总数的 2.0039%），其中，通过集中竞价交易方式减持不超过 809,700 股；通过大宗交易方式减持不超过 813,000 股，拟减持期间为 2025 年 7 月 25 日至 2025 年 10 ...

安杰思公告，股东苏州元生私募基金管理合伙企业（有限合伙）－苏州工业园区新建元二期创业投资企 业（有限合伙）原拟于2025年7月25日至10月23日减持不超过162.27万股（2.0039%），实际于7月25日 通过集中竞价减持34.58万股，占0.4270%，成交价76～76.6元/股，套现2641.48万元；本次减持计划期 限届满终止，仍有127.69万股未减持，当前持股288.8万股，占3.5664%。 ...

Company Overview - Anjess Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, established on December 6, 2010, and listed on May 19, 2023 [1] - The company specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with main business revenue composition as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1] Stock Performance - As of October 23, Anjess's stock price decreased by 2.12%, trading at 64.52 CNY per share, with a total market capitalization of 5.234 billion CNY [1] - Year-to-date, the stock price has increased by 10.64%, but it has declined by 3.69% over the last five trading days, 12.36% over the last twenty days, and 10.61% over the last sixty days [1] Financial Performance - For the first half of 2025, Anjess achieved operating revenue of 302 million CNY, representing a year-on-year growth of 14.56%, and a net profit attributable to shareholders of 126 million CNY, with a year-on-year growth of 1.26% [2] - Since its A-share listing, Anjess has distributed a total of 239 million CNY in dividends [3] Shareholder Information - As of October 20, the number of shareholders for Anjess was 5,728, an increase of 2.89% from the previous period, with an average of 7,255 circulating shares per shareholder, a decrease of 2.47% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited exited the list of the top ten circulating shareholders [3]

Group 1 - The stock price of Anjiasi (688581.SH) fell by 4.26% to 68.84 yuan, indicating it is currently in a state of decline since its IPO [1] - Anjiasi was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 19, 2023, with an initial offering price of 125.80 yuan per share and a total of 14.47 million shares issued [1] - The total amount raised from the IPO was 182.03 million yuan, with a net amount of 165.10 million yuan after deducting issuance costs, which was 88.03 million yuan more than originally planned [1] Group 2 - The funds raised are intended for projects including the production of 10 million medical endoscope devices, upgrading marketing service networks, and establishing a minimally invasive medical device R&D center [1] - The total issuance costs amounted to 16.93 million yuan, with the lead underwriter, CITIC Securities, receiving 12.89 million yuan in underwriting fees [1] - Strategic placement was conducted by the underwriter, with Zhongzheng Investment subscribing to 3.30% of the shares, amounting to approximately 60 million yuan [2] Group 3 - Anjiasi plans to distribute a cash dividend of 14.5 yuan (including tax) for every 10 shares and issue 4 bonus shares for every 10 shares, with the record date set for June 20, 2024 [2]

证券代码：688581 证券简称：安杰思 公告编号：2025-062 杭州安杰思医学科技股份有限公司 2023年限制性股票激励计划首次授予部分第二个归属 期及预留授予部分第一个归属期归属结果暨股票上市 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 143,285股。 本次股票上市流通总数为143,285股。 本次股票上市流通日期为2025 年 10 月 15 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，杭州安杰思医学科技股份有限公司（以下简称"公司"） 于 2025 年 10 月 10 日收到中国证券登记结算有限责任公司上海分公司出具的《证 券变更登记证明》，公司已完成 2023 年限制性股票激励计划（以下简称"本激励 计划"）首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记工作。 现将有关情况公告如下： 同日，公司召开第二届监事会第四次会议，审议通过了《关于公司<202 ...

Core Viewpoint - Shanghai Xinxiang Microelectronics Co., Ltd. (hereinafter referred to as "Xinxiang Micro") announced a share reduction plan by its major shareholder, Kexin Chip (Hong Kong) Co., Ltd. (hereinafter referred to as "Kexin Chip"), due to its own funding needs [1][2]. Shareholding Situation - Kexin Chip holds 28,619,320 shares of Xinxiang Micro, accounting for 6.23% of the total share capital, with these shares acquired before the company's initial public offering (IPO) [2]. - The planned reduction involves a maximum of 4,595,294 shares, which is up to 1% of the total share capital, to be executed through centralized bidding from October 29, 2025, to January 27, 2026 [2]. Reduction Commitment - Kexin Chip previously made commitments regarding shareholding ratios, quantities, holding periods, reduction methods, and prices, including not selling shares held before the IPO during the lock-up period and adhering to regulations post-lock-up [3]. - The current reduction plan aligns with previously disclosed commitments [3].